Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108766 | 0.93 | MTNR1A (0.58) | CHRM2CHRM1CHRM3TDP1TAAR1 | |
| SCHEMBL5517703 | 0.91 | CHRM2 (0.66) | CHRM2CHRM1CHRM3TDP1TAAR1 | |
| SCHEMBL5524054 | 0.89 | CHRM2 (0.68) | CHRM2CHRM1CHRM3TDP1TAAR1 | |
| SCHEMBL26268316 | 0.88 | CHRM2 (0.67) | CHRM2CHRM1CHRM3TDP1TAAR1 | |
| SCHEMBL5101834 | 0.88 | CHRM2 (0.66) | CHRM2CHRM1CHRM3TDP1TAAR1 | |
| SCHEMBL27904935 | 0.88 | CHRM2 (0.66) | CHRM2CHRM1CHRM3TDP1TAAR1 | |
| SCHEMBL7790532 | 0.87 | CNR1 (0.67) | CHRM2CHRM1CHRM3TAAR1MAPT | |
| SCHEMBL19062086 | 0.87 | CHRM2 (0.60) | CHRM2CHRM1CHRM3TDP1TAAR1 | |
| SCHEMBL23958512 | 0.83 | CHRM2 (0.56) | CHRM2CHRM1CHRM3TDP1TAAR1 | |
| SCHEMBL27922884 | 0.82 | CHRM2 (0.59) | CHRM2CHRM1CHRM3TAAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179926-B2 | Aryloxyalkylamine NK-1/SSRI inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-20 | — | — | US | claimed |
| US-20060020019-A1 | Aryloxyalkylamine NK-1/SSRI inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | claimed |
| WO-2021213358-A1 | BORON-CONTAINING COMPOUNDS AND APPLICATION THEREOF | 江苏先声药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-7435729-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7179926-B2 | Aryloxyalkylamine NK-1/SSRI inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20060020019-A1 | Aryloxyalkylamine NK-1/SSRI inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6686351-B2 | PARTIALLY HYDROGENATED FUSED INDENE, NAPHTHALENE, ISOINDOLE, ISOQUINOLINE, BENZOAZEPINE AND BENZOCYCLOHEPTENE DERIVATIVES SUBSTITUTED BY A HYDROXY GROUP OR DERIVATIVE AND AN ARYL OR N-HETEROARYL GROUP | SIGNAL PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6593322-B1 | Methods are disclosed for modulating ER- beta in cell and/or tissues expressing the same, including cells and/ or tissue that preferentially ER- beta . Methods for treating estrogen-related conditions are also disclosed, including | SIGNAL PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6436923-B1 | ESTROGEN ANTAGONISTS AND/OR AGONISTS FOR TREATING ESTROGEN-RELATED CONDITIONS | SIGNAL PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020019-A1 | Aryloxyalkylamine NK-1/SSRI inhibitors | TPH1, SLC6A4, HTR1A | CHRM2 1098/4885CHRM1 692/4885CHRM3 719/4885 |
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESR2, ESRRA | CHRM2 950/4885CHRM1 1722/4885CHRM3 624/4885 |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | CHRM2 987/4885CHRM1 1821/4885CHRM3 648/4885 |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | CHRM2 990/4885CHRM1 1822/4885CHRM3 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.